Results of a phase I study of RAD001 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma.

8032 Background: Lenalidomide (Len) plus dexamethasone (Dex) is approved for the treatment of relapsed or relapsed/refractory multiple myeloma (MM) patients following ≥1 prior therapy. RAD001, an m...